MetX funded by $1M grant from Metrodora Foundation to accelerate research for complex multisystem disordersSALT LAKE CITY, UT and OXFORD, UK – 18 September 2024 – PrecisionLife, a leading clinical-stage precision medicine company focused on chronic diseases, and Metrodora Institute, an advanced US research and healthcare center, have begun sharing the first research results with participants from Metrodora’s MetX study. The Metrodora Foundation, a leading 501(c)(3) nonprofit, provided critical funding to launch MetX with a generous $1M grant. This marks a significant breakthrough in…
Sanger sequencing is utilised to understand the arrangement of nucleotides within a sequence of DNA. This technique offers 99.99% reliability, enhanced sensitivity due to its sequencing depth, and the ability to provide sequencing information from even the most deteriorated DNA samples.
Read our latest blog here:
https://sourcebioscience.com/how-can-you-benefit-from-outsourcing-seque…
Applications open for Discovery Park’s ‘Discovery Spark’ programme
Prize package worth over £50,000, including free lab or office space for one year at Discovery Park and a package of support from a number of specialist partners.
Deadline for initial applications closes midnight on 24th September 2024
Sandwich, Kent, UK / 12 September 2024 / Leading science and innovation campus, Discovery Park, in Sandwich, Kent has launched applications for the third cohort of its immersive business growth competition, ‘Discovery Spark’.
The programme equips early…
Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule
Stevenage, UK, 5 September 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces its conference attendance programme for the remainder of 2024.
Forthcoming events include:
• ISCT Europe Regional Meeting, 4 – 6 September in Gothenburg - speaking
• Healthtech Innovation Day, 17 – 18 September in Paris - speaking, investor meetings
• Sachs Biotech in Europe Forum,…
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Stevenage, UK, 5 August 2024 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation.
It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used to support its discovery programme for a treatment for Amyotrophic Lateral Sclerosis (ALS) (also known as…
Read eNews for September here
Featuring:
✅ Tony Jones, CEO, One Nucleus monthly news
✅ Are You Targeting Your Advertising Spend for the Best Return? by Alicia Gailliez
✅ Has Biotech Investment Turned a Corner? - BioIndustry Association (BIA)
✅ What’s Hot in the Diagnostic Deal Space? - PharmaVentures
✅ What were the top 10 locations for UK Life Science investment in the UK in 1H 2024? - Pioneer Group
✅ The Role of Innovative R&D and GenAI in Helping to Tackle AMR - Deloitte
✅ Don't Miss Your Opportunities at BIO-Europe - Deadlines Approaching! -EBD Group
Sponsored by…
Merck’s EMEA Advance Biotech Grant Program
Merck’s EMEA Advance Biotech Grant Program https://informaconnect.com/bioeurope/merck-advance-biotech-grant/ is designed to support emerging biotech companies on the forefront of innovative drug development. Targeted at biotechs with a focus on novel modalities and therapeutics, this program aids companies with at least one biologic in the pipeline, particularly those working on mAbs, ADCs, mRNA, gene therapy, cell therapy, and vaccines.
The program offers significant prizes: the winner receives €148,400 in bioprocessing technologies, consultation…
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing to Advance Clinical Programmes in Immuno-Oncology and Inflammatory Bowel Disease Through to Data Readout
Cambridge, UK – 27 August 2024: Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce that it has received regulatory approvals to initiate clinical studies for its first two programmes in advanced melanoma (MELODY-1…
The August edition of our People Pathways newsletter is out now! Read the newsletter here.You can read about:✅ One Nucleus upcoming courses - don't forget, as a One Nucleus member, you can access discounts up to 30%;✅ Our upcoming BLSA SIG webinar on the Green Business Impact Programme jointly delivered by Allia and PECT;✅ EBD Academy courses - member savings available;and more...
WEST CHESTER, Pa. and CAMBRIDGE, England – Wednesday, August 21, 2024 – Supreme Group today announced the acquisition of BioStrata, an award-winning agency offering comprehensive marketing communication services to the life science sector. Based in Cambridge, UK, and servicing clients globally, BioStrata has helped more than 200 life science organizations achieve their business goals across life science research tools, medical devices, diagnostics, contract research and manufacturing, biopharma, and other areas.
This strategic addition, backed by growth-oriented private equity firm…